Axogen, Inc. (AXGN) Stock
AXGN has an Alpha Score of 52 out of 100 (weak), computed on Nov 6, 2026 from 2 of 4 sub-scores. 1 member of Congress disclosed 1 trade in AXGN since 2019: 1 purchase and 0 sales, most recently Donna Shalala (purchase, Apr 16, 2019). 6 of the hedge funds AlphaScala tracks reported AXGN in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $62.86M. Company insiders reported 0 open-market buys and 1 sale on SEC Form 4 in the 90 days to Nov 10, 2026.
What is AXGN's Alpha Score?
How it works →Alpha Score of 52 reflects moderate overall profile with strong momentum, weak quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 6, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Axogen, Inc. (AXGN)?
Most recent: Donna Shalala (purchase, Apr 16, 2019); records start Apr 16, 2019.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Donna Shalala D-FL · House | 2019-04-16 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 9, 2026.
See all AXGN political trades →Which hedge funds own AXGN?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 1.36M | $62.86M | +455% |
| Marshall Wace | 298K | $13.78M | +784% |
| D.E. Shaw David Shaw | 278K | $12.83M | +5% |
| Point72 Steve Cohen | 225K | $10.38M | +11% |
| Millennium Management Israel Englander | 27K | $1.26M | -97% |
| Blackstone | 15K | $714.1K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Axogen, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 2, 26 | Tyndall Joseph A. | Director | SELL | 3.5K | $174K |
| Aug 11, 26 | Wendell Amy Mcbride | Director | SELL | 13.4K | $647K |
| Aug 10, 26 | Began Marc A | EVP & General Counsel | SELL | 67.5K | $3.2M |
| Aug 7, 26 | Weiler Kathy Johnson | Director | SELL | 14.2K | $641K |
SEC Form 4 filings as of Nov 10, 2026
See cluster-buy signals across all tickers →What are AXGN's key statistics?
Key statistics as of Nov 9, 2026
How does AXGN's valuation compare with the Healthcare sector?
| Metric | AXGN | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -13.36% | 3.60% | 175 |
| Return on equity | -17.88% | 2.93% | 201 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 11, 2026). P/E excludes loss-making companies.
AXGN price chart
Powered by TradingViewWhat does Axogen, Inc. do?
Axogen Inc. is a leading developer and marketer of innovative surgical solutions for peripheral nerve regeneration and repair. The company specializes in biologically active technologies, including the Avance Nerve Graft, an off-the-shelf processed human nerve allograft that bridges severed peripheral nerves without requiring a second surgical site. Its portfolio also features the AxoGuard Nerve Connector and AxoGuard Nerve Protector, porcine submucosa extracellular matrix products that enable tensionless nerve repairs and protection; the AxoGuard Nerve Cap for nerve end treatment; and the Avive Soft Tissue Membrane for soft tissue management. Additionally, Axogen offers the AxoTouch Two-Point Discriminator, a tool for assessing skin innervation density. These products serve hand surgeons, reconstructive plastic surgeons, oral and maxillofacial surgeons, and other specialists treating nerve injuries across the body. Axogen Inc. provides these solutions to healthcare providers in the United States, Canada, Europe, South Korea, and other international markets, aiming to restore nerve function, sensation, and patient quality of life. Headquartered in Alachua, Florida, the company focuses on advancing peripheral nerve repair as a standard of care in surgical practice.